✦ LIBER ✦

A Phase II study of the safety, pharmacokinetics and efficacy of IncelTM (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in advanced hormone refractory prostate cancer (HRPC)

✍ Scribed by Einstein, A.; Lush, R.; Rago, R.; Bubley, G.; Henner, W.D.; Chatta, G.; Shepard, R.; Merica, E.A.; Harding, M.W.; Dalton, W.S.

Book ID: 123316195
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 149 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(99)81827-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of the MDR inhibitor

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer

✍ Randall P. Rago; Albert Einstein; Richard Lush; Tomasz M. Beer; Yoo-Joung Ko; W. 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 238 KB

A Phase II study of IncelTM (biricodar,

A Phase II study of IncelTM (biricodar, VX-710) in combination with paclitaxel in women with advanced breast cancer refractory to paclitaxel

✍ Toppmeyer, D.; Seidman, A.; Overmoyer, B.; Pollak, M.; Verma, S.; Russell, C.; T 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Phase II randomised trial of docetaxel (

Phase II randomised trial of docetaxel (D), estramustine (E) and prednisone (P) — Two schedules — versus mitoxantrone (M) and prednisone in patients (PTS) with hormone refractory prostate cancer (HRPC)

✍ S. Qudard; E.B. Banu; E. Voog; H. Hardy-Bessard; C. Linassier; P. Beuzeuboe; A. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 187 KB

A Phase II Study of the MDR Inhibitor Bi

A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy

✍ Michael V. Seiden; Kenneth D. Swenerton; Ursula Matulonis; Susan Campos; Peter R 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 88 KB

211 POSTER Results of a phase II study o

211 POSTER Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)

✍ R. DeJager; L. Roman; N. Lopatkin; P. Karlov; H.B. Breitz; R. Earhart 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

A phase II study of the safety and effic

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

✍ Leena Gandhi; Matthew W. Harding; Marcus Neubauer; Corey J. Langer; Melvin Moore 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views